Psychedelic Alpha: The Balance at MAPS Between Public Benefit and Private Profit

Summary: “At this moment, when two successful Phase 3 studies of MDMA-assisted therapy for PTSD have brought us closer to potential FDA approval than ever before, MAPS and MAPS PBC must faithfully retain our values against the sometimes diametric values of the systems in which we operate.” – Rick Doblin, Ph.D.

Originally appearing here (Archived)